# A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors

> **NCT07744763** · PHASE1,PHASE2 · RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SYS6041

## Key facts

- **NCT ID:** NCT07744763
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-28
- **Primary completion:** 2027-03-28
- **Final completion:** 2027-03-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744763, "A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07744763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*